Prijevod "adenokarcinom" na engleski jezik:
Rječnik Hrvatski-Engleski
Adenokarcinom - prijevod :
Primjeri (Vanjski izvori, nisu pregledani)
| Adenokarcinom | Adenocarcinoma |
| Adenokarcinom | Adenocarcinoma (N 847) |
| Adenokarcinom pankreasa | Breast cancer |
| Adenokarcinom želuca | Gastric adenocarcinoma |
| Adenokarcinom (N 847) | Adenocarcinoma (N 847) |
| Adenokarcinom (N 847) | Adenocarcinoma (N 847) |
| Adenokarcinom (N 847) | Adenocarcinoma (N 847) |
| Rak želuca i adenokarcinom gastroezofagealnog spoja | Gastric cancer and gastro oesophageal junction (GEJ) adenocarcinoma |
| kronična mijelomonocitna leukemija(2)(4), adenokarcinom gušterače(5) | Chronic myelomonocytic leukaemia(2)(4), pancreatic adenocarcinoma(5) |
| gastrični karcinom (rak želuca) u naprednom stadiju ili karcinom područja u kojem jednjak (ezofagus) ulazi u želudac (poznat pod nazivom adenokarcinom gastroezofagealnog spoja). | advanced gastric cancer (cancer of the stomach) or cancer of the area where the gullet (oesophagus) enters the stomach (known as gastro oesophageal junction adenocarcinoma). |
| Dodatno, zabilježen je adenokarcinom jejunuma kod mužjaka štakora koji je primao najnižu ispitivanu dozu (margina plazmatske izloženosti kod životinje u odnosu na ljude od otprilike 10 puta). | In addition, a jejunal adenocarcinoma was observed in a male rat administered the lowest dose tested (animal human plasma exposure margin of approximately 10 fold). |
| U eksploracijskoj analizi je utvrđeno da je opseg koristi liječenja lijekom Avastin u pogledu ukupnog preživljenja bio manje izražen u podskupini bolesnika koji histološki nisu imali adenokarcinom. | In an exploratory analysis, the extent of Avastin benefit on overall survival was less pronounced in the subgroup of patients who did not have adenocarcinoma histology. |
| Abraxane je indiciran kao monoterapija za karcinom dojke, u kombinaciji s gemcitabinom za adenokarcinom pankreasa ili u kombinaciji s karboplatinom za karcinom nemalih stanica pluća (vidjeti dio 4.1). | Abraxane is indicated as monotherapy for breast cancer, in combination with gemcitabine for pancreatic adenocarcinoma, or in combination with carboplatin for non small cell lung cancer (see section 4.1). |
| Cervikalna intraepitelna neoplazija (CIN) stupnja 2 i 3 (CIN 2 3) i cervikalni adenokarcinom in situ (AIS) su u kliničkim ispitivanjima korišteni kao surogat markera za karcinom cerviksa. | Cervical Intraepithelial Neoplasia (CIN) grade 2 and 3 (CIN2 3) and cervical adenocarcinoma in situ (AIS) were used in the clinical trials as surrogate markers for cervical cancer. |
| U kliničkim su se ispitivanjima cervikalna intraepitelna neoplazija (CIN) stupnja 2 3 (umjerena do teška displazija) te adenokarcinom in situ (AIS) koristili kao zamjenski markeri raka vrata maternice. | Cervical Intraepithelial Neoplasia (CIN) Grade 2 3 (moderate to high grade dysplasia) and adenocarcinoma in situ (AIS) were used in the clinical trials as a surrogate marker for cervical cancer. |
| Docetaxel Accord u kombinaciji s cisplatinom i 5 fluorouracilom je indiciran za liječenje bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji nisu prethodno primali kemoterapiju za metastatsku bolest. | Docetaxel Accord in combination with cisplatin and 5 fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. |
| DOCETAXEL KABI je u kombinaciji s cisplatinom i 5 fluorouracilom indiciran za liječenje bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja koji nisu prethodno primali kemoterapiju za metastatsku bolest. | DOCETAXEL KABI in combination with cisplatin and 5 fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. |
| DOCETAXEL KABI je u kombinaciji s cisplatinom i 5 fluorouracilom indiciran za liječenje bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji nisu prethodno primali kemoterapiju za metastatsku bolest. | DOCETAXEL KABI in combination with cisplatin and 5 fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. |
| Docetaxel Mylan u kombinaciji s cisplatinom i 5 fluorouracilom je indiciran za liječenje bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji nisu prethodno primali kemoterapiju za metastatsku bolest. | Docetaxel Mylan in combination with cisplatin and 5 fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. |
| Docetaksel Teva u kombinaciji s cisplatinom i 5 fluorouracilom je indiciran za liječenje bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji nisu prethodno primali kemoterapiju za metastatsku bolest. | Docetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. |
| Docetaxel Winthrop u kombinaciji s cisplatinom i 5 fluorouracilom je indiciran za liječenje bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji nisu prethodno primali kemoterapiju za metastatsku bolest. | Docetaxel Winthrop in combination with cisplatin and 5 fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. |
| Rani rak dojke u ispitivanju BO16348 bio je ograničen isključivo na operabilni, primarni, invazivni adenokarcinom dojke, s pozitivnim ili negativnim aksilarnim čvorovima, ako je promjer tumora iznosio najmanje 1 cm. | Early breast cancer in the BO16348 Study was limited to operable, primary, invasive adenocarcinoma of the breast, with axillary nodes positive or axillary nodes negative if tumors at least 1 cm in diameter. |
| Rani rak dojke u ispitivanju HERA bio je ograničen isključivo na operabilni, primarni, invazivni adenokarcinom dojke, s pozitivnim ili negativnim aksilarnim čvorovima ako je promjer tumora iznosio najmanje 1 cm. | Early breast cancer in the HERA trial was limited to operable, primary, invasive adenocarcinoma of the breast, with axillary nodes positive or axillary nodes negative if tumors at least 1 cm in diameter. |
| Dostupni su podaci za samo 45 bolesnika čiji se odgovor mogao ocijeniti u Ispitivanju 1005, a koji su imali prethodno liječen NSCLC koji nije bio adenokarcinom (uključujući 22 bolesnika sa SCC om). | Information is available from 45 response evaluable patients with previously treated non adenocarcinoma NSCLC (including 22 patients with SCC) in Study 1005. |
| Provedena je multicentrična, randomizirana studija otvorenog tipa da bi se procijenila sigurnost i djelotvornost docetaksela u liječenju bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji prije toga nisu primali kemoterapiju za metastatsku bolest. | A multicenter, open label, randomized study was conducted to evaluate the safety and efficacy of docetaxel for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease. |
| Provedena je multicentrična, randomizirana studija otvorenog tipa da bi se procijenila sigurnost i djelotvornost docetaksela u liječenju bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji prije toga nisu primali kemoterapiju za metastatsku bolest. | A multicenter, open label, randomized study, was conducted to evaluate the safety and efficacy of docetaxel for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease. |
| Provedena je multicentrična, randomizirana studija otvorenog tipa da bi se procijenila sigurnost primjene i djelotvornost docetaksela u liječenju bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji prije toga nisu primali kemoterapiju za metastatsku bolest. | A multicenter, open label, randomized study was conducted to evaluate the safety and efficacy of docetaxel for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease. |
| Provedena je multicentrična, randomizirana studija otvorenog tipa da bi se procijenila sigurnost primjene i djelotvornost docetaksela u liječenju bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja koji prije toga nisu primali kemoterapiju za metastatsku bolest. | A multicenter, open label, randomized study, was conducted to evaluate the safety and efficacy of docetaxel for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease. |
| Provedena je multicentrična, randomizirana studija otvorenog tipa da bi se procijenila sigurnost primjene i djelotvornost docetaksela u liječenju bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji prije toga nisu primali kemoterapiju za metastatsku bolest. | A multicenter, open label, randomized study, was conducted to evaluate the safety and efficacy of docetaxel for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease. |
| Nuspojave su procijenjene u 421 bolesnika liječenog Abraxaneom u kombinaciji s gemcitabinom i 402 bolesnika liječena gemcitabinom kao monoterapijom koji su primali prvu liniju sistemskog liječenja za metastatski adenokarcinom pankreasa u randomiziranom kontroliranom otvorenom ispitivanju faze III. | Adverse reactions were assessed in 421 patients treated with Abraxane in combination with gemcitabine and 402 gemcitabine monotherapy treated patients receiving first line systemic treatment for metastatic adenocarcinoma of the pancreas in a phase III randomized, controlled, open label trial. |
| Bolesnice pogodne za uključivanje u ispitivanje imale su perzistentni, recidivirajući ili metastatski planocelularni karcinom, adenoplanocelularni karcinom ili adenokarcinom cerviksa koji nije odgovorio na kurativno liječenje kirurškim zahvatom i ili radioterapijom i prethodno nisu bile liječene bevacizumabom ili drugim VEGF inhibitorima niti lijekovima koji djeluju na VEGF receptore. | Eligible patients had persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which was not amenable to curative treatment with surgery and or radiation therapy and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. |
| Incidencija tumora jetre u štakora bila je povećana u mužjaka (adenom i karcinom) i ženki (adenom) pri dozi od 100 i 250 mg kg dan incidencija tumora maternice (adenokarcinom endometrija) i maternice i cerviksa (karcinom skvamoznih stanica) bila je povećana pri dozi od 250 mg kg dan. | In rats, the incidence of liver tumours was increased in males (adenoma and carcinoma) and females (adenoma) at 100 and 250 mg kg day the incidence of tumours of the uterus (endometrial adenocarcinoma) and uterus and cervix (squamous cell carcinoma) were increased at 250 mg kg day. |
